| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 4797 | 2017 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1878 | 2019 |
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 | 905 | 2021 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119, 2020 | 592 | 2020 |
| Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up T Martin, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, D Avigan, ... Journal of Clinical Oncology 41 (6), 1265, 2023 | 254 | 2023 |
| Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited A Deol, LG Lum Cancer treatment reviews 36 (7), 528-538, 2010 | 187 | 2010 |
| CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma D Madduri, JG Berdeja, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... Blood 136, 22-25, 2020 | 133 | 2020 |
| Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience LJ Nastoupil, MD Jain, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 132 | 2018 |
| Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma OO Oluwole, K Bouabdallah, J Muñoz, S De Guibert, JM Vose, NL Bartlett, ... British journal of haematology 194 (4), 690-700, 2021 | 112 | 2021 |
| Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma SS Neelapu, CA Jacobson, OO Oluwole, J Munoz, A Deol, DB Miklos, ... Blood, The Journal of the American Society of Hematology 135 (23), 2106-2109, 2020 | 111 | 2020 |
| Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia RT Maziarz, M Levis, MM Patnaik, BL Scott, SR Mohan, A Deol, ... Bone marrow transplantation 56 (5), 1180-1189, 2021 | 109 | 2021 |
| Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma SS Neelapu, CA Jacobson, A Ghobadi, DB Miklos, LJ Lekakis, ... Blood, The Journal of the American Society of Hematology 141 (19), 2307-2315, 2023 | 104 | 2023 |
| Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy JY Spiegel, S Dahiya, MD Jain, J Tamaresis, LJ Nastoupil, MT Jacobs, ... Blood, The Journal of the American Society of Hematology 137 (13), 1832-1835, 2021 | 97 | 2021 |
| Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1 SS Neelapu, FL Locke, NL Bartlett, L Lekakis, D Miklos, CA Jacobson, ... Blood, The Journal of the American Society of Hematology 128 (22), LBA-6-LBA-6, 2016 | 76 | 2016 |
| Updated results from CARTITUDE-1: phase 1b/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with … T Martin, SZ Usmani, JG Berdeja, A Jakubowiak, M Agha, AD Cohen, ... Blood 138, 549, 2021 | 68 | 2021 |
| Radius: a phase 2 randomized trial investigating standard of care±midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML RTT Maziarz, MM Patnaik, BL Scott, SR Mohan, A Deol, SD Rowley, ... Blood 132, 662, 2018 | 67 | 2018 |
| Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the … E Warlick, KW Ahn, TL Pedersen, A Artz, M De Lima, M Pulsipher, ... Blood, The Journal of the American Society of Hematology 119 (17), 4083-4090, 2012 | 67 | 2012 |
| Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease D Bhutani, G Dyson, R Manasa, A Deol, V Ratanatharathorn, L Ayash, ... Biology of Blood and Marrow Transplantation 21 (1), 159-164, 2015 | 63 | 2015 |
| Long-term (≥ 4 year and≥ 5 year) overall survival (OS) by 12-and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene … C Jacobson, FL Locke, A Ghobadi, DB Miklos, LJ Lekakis, OO Oluwole, ... Blood 138, 1764, 2021 | 58 | 2021 |
| Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR … MD Jain, MT Jacobs, LJ Nastoupil, JY Spiegel, G Feng, Y Lin, ... Blood 134, 245, 2019 | 57 | 2019 |
